Weekly Wisdom from Kauffman: Breaking Down Barriers to Life Sciences Commercialization

Rate This
  • 1
  • 2
  • 3
  • 4
  • 5
Christina Hernandez Sherwood, eMed Editor, MedCity News

Weekly Wisdom from Kauffman: Breaking Down Barriers to Life Sciences Commercialization

Because life sciences entrepreneurship thrives on harnessing new technologies, spurring innovation, and growing companies, the Kauffman Foundation met in 2003 with the Panel of Advisors on the Life Sciences to help advance those goals.

Two main themes emerged regarding barriers to commercialization in the life sciences:

  • University technology transfer expertise and commercialization have not kept pace with the increase and breadth of research funding in recent years. More than 50 percent of the revenues from licenses in the life sciences is now clustered in just 10 universities and is associated with a very small number of commercial products and services.
  • Similarly, relative to total university population, there are a small number of universities where the organization and operation of technology transfer is optimal. There is widespread agreement that many technology transfer offices are under-funded, insufficiently staffed, and not an integral part of the university research enterprise.

Going forward, the challenge is to identify and replicate the processes that facilitate swift movement of technology from the academic world to American commerce.

Weekly Wisdom from Kauffman is a regular feature on eMed highlighting insightful research from the Kauffman Foundation. Do you have a favorite Kauffman research insight that could help life science entrepreneurs? Send it to mailto:emededitor@kauffman.org .

comments powered by Disqus